4.5 Article

Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture

期刊

OSTEOPOROSIS INTERNATIONAL
卷 25, 期 6, 页码 1797-1806

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-014-2698-1

关键词

Elderly; Health economics; Hip fracture; Supplementation; Model; Vitamin D

资金

  1. Merck Sharp Dohme Laboratories France
  2. BMS
  3. Sanofi
  4. Medtronic
  5. Abbott
  6. MSD
  7. Lilly
  8. Novartis
  9. AMGEN
  10. Bongrain
  11. UCB
  12. Genevrier
  13. GSK
  14. Merck
  15. Servier
  16. Candia
  17. Roche
  18. Roche-Chugai
  19. Ipsen

向作者/读者索取更多资源

We performed a cost-effectiveness analysis of four vitamin D supplementation strategies for primary prevention of hip fracture among the elderly population and found that the most cost-effective strategy was screening for vitamin D insufficiency followed by adequate treatment to attain a minimum 25(OH) serum level. Vitamin D supplementation has a demonstrated ability to reduce the incidence of hip fractures. The efficiency of lifetime supplementation has not yet been assessed in the population over 65 years without previous hip fracture. The objective was to analyze the efficiency of various vitamin D supplementation strategies for that population. A Markov micro-simulation model was built with data extracted from published studies and from the French reimbursement schedule. Four vitamin D supplementation strategies were evaluated on our study population: (1) no treatment, (2) supplementation without any serum level check; (3) supplementation with a serum level check 3 months after initiation and subsequent treatment adaptation; (4) population screening for vitamin D insufficiency followed by treatment based on the vitamin D serum level. Treat, then check and screen and treat were two cost-effective strategies and dominated treat without check with incremental cost-effectiveness ratios of a,not sign5,219/quality-adjusted life-years (QALY) and a,not sign9,104/QALY, respectively. The acceptability curves showed that over a,not sign6,000/QALY, the screen and treat strategy had the greatest probability of being cost-effective, and the no treatment strategy would never be cost-effective if society were willing to spend over a,not sign8,000/QALY. The sensitivity analysis showed that among all parameters varying within realistic ranges, the cost of vitamin D treatment had the greatest effect and yet remained below the WHO cost-effectiveness thresholds. Population screening for vitamin D insufficiency followed by treatment based on the vitamin D serum level is the most cost-effective strategy for preventing hip fracture occurrence in the population over 65 years old.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据